Equipoise – Boldenone Undecylenate (Bold200, Boldenone, Baldebal-H)
Ciccone Equipoise Combo450 (See Boldenone esters: Undecylenate, see Cypionate, Acetate)
Primabolin Tabs – Methenolone Acetate
Primabolin Depot – Methenolone Enathate (Alphabolin, Primabolin Depot)
Masteron100 – Drostanalone Propionate
Masteron200 – Drostanolone Enanthate
Winstrol Depot – Stanozolol
Winstrol Tabs – Stanozolol
Oxandrolone – Oxandrolone (Anavar)
When you supplement with Dbol, and this goes for all anabolic steroids it is imperative you live a healthy lifestyle that promotes the continuation of good health. If your blood pressure and cholesterol levels are healthy prior to supplementation, and you shouldn't be supplementing otherwise, continue to live in a way that promotes the continuation of such healthy levels; in-fact, give it more attention. This should not be all that hard to do; after all, you're supplementing for the purpose of performance enhancement, and an unhealthy lifestyle does not promote this end. You bet, this means avoiding excess or heavy alcohol consumption, but it also needs to be avoided due to the C17-aa nature of this steroid as discussed above. Heavy alcohol consumption is extremely hard on the liver, and you don't need the added stress; more so, alcohol itself is the most anti-performance thing you could ever put into your body. While you should avoid excess alcohol, and all alcohol if you want to do things right, you are also encouraged to avoid all over the counter (OTC) medications when possible. Many OTC meds carry extremely strong hepatotoxic natures, some even more so than many anabolic steroids, and their use must be limited to only when truly needed.
Several studies evaluating the effect of tamoxifen (the active ingredient contained in Nolvadex) on antithrombin III, fibrinogen, and platelets have been unable to provide clarification of thromboembolic risk in tamoxifen treated patients. In addition, despite its antiestrogenic activity, evidence is lacking to support a tamoxifen-associated increase in cardiovascular risk. One study concluded that tamoxifen and prior surgery, fracture, or immobilization were associated with a significantly increased risk of developing a venous thromboembolism. Another study found a decreased risk of myocardial infarction.
In one study of 8 premenopausal and 46 postmenopausal women with advanced breast cancer, tamoxifen 10 mg three times daily produced no effect on total cholesterol, triglycerides, or free fatty acids. A significant increase in HDL and subsequent increase in HDL/total cholesterol ratio were noted in addition to a significant reduction in LDL cholesterol. Overall, tamoxifen appeared to exert a favorable effect on the lipid profile.
One five year study has reported total serum cholesterol, LDL cholesterol, and lipoprotein to be significantly lower and apolipoprotein A1 levels significantly higher in 30 tamoxifen recipients compared with the 32 patients who did not receive tamoxifen. Apolipoprotein B levels were reported to have increased to a greater extent in the group which did not receive tamoxifen. After five years, fibrinogen level decreases and triglyceride level increases in the tamoxifen group were of borderline statistical significance. In general, the favorable changes in the lipid, lipoprotein, and fibrinogen levels seen early in tamoxifen therapy in postmenopausal women were reported to have continued to be seen five years into the treatment regimen. [ Ref ]